natgillin/translations-raw huggingface dataset:
Frequency cannot be estimated from available data.
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
Novartis Hrvatska d.o.o.
Hrvatska Pliva Hrvatska d.o.o
The zoledronic acid group revealed approximately 2.5 mm less height loss compared to placebo (95% CI: 1.6 mm, 3.5 mm) [p<0.0001].
V skupini z zoledronsko kislino je bilo zniževanje telesne višine za približno 2,5 mm manjše kot v skupini s placebom (95 % IZ: 1,6 mm, 3,5 mm) [p<0,0001].
Zoledronic acid Teva Generics is supplied in packs of 1, 5 or 10 bottles.
Zdravilo Zoledronska kislina Teva Generics je na voljo v pakiranjih po 1, 5 ali 10 plastenk.
Single and multiple 5 and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients yielded the following pharmacokinetic data, which were found to be dose independent.
Enkratne in večkratne 5-minutne in 15-minutne infuzije po 2, 4, 8 in 16 mg zoledronske kisline so pri
- if you have a kidney problem, or used to have one.
- če imate ali ste kdaj prej imeli težave z ledvicami.
Solution for infusion multipack: 5 bags x 100 ml multipack: 10 bags x 100 ml
raztopina za infundiranje skupno pakiranje: 5 vreč x 100 ml skupno pakiranje: 10 vreč x 100 ml intravenska uporaba
In patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following zoledronic acid administration (see section 4.4).
Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, dvakrat na dan vsaj 10 dni po uporabi zoledronske kisline (glejte poglavje 4.4).
Only clear solution free from particles and discoloration should be used.
Uporabiti smete samo bistro raztopino brez delcev in nespremenjene barve.
Zoledronic acid (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate.
Način uporabe intravenska uporaba Zoledronska kislina (5 mg v 100 ml raztopine, pripravljene za infuzijo) se aplicira prek infuzijskega sistema s prezračevanjem in sicer s stalno hitrostjo infundiranja.
- if you have had some or all of the parathyroid glands in your neck surgically removed.
- če so vam deloma ali v celoti kirurško odstranili žleze obščitnice.
Zoledronic acid-treated patients aged 75 years and older exhibited a 60% reduction in the risk of vertebral fractures compared to placebo patients (p<0.0001).
Pri bolnikih, ki so bili stari 75 let ali starejši in so prejemali zoledronsko kislino, je bilo tveganje za zlome vretenc za 60 % manjše v primerjavi z bolniki, ki so prejemali placebo (p<0,0001).
Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a mean duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
zdravljenih z risedronatom, ki so bili vključeni v študijo podaljšanega opazovanja, je bil po povprečnem trajanju spremljanja 3,8 let od časa odmerjanja delež bolnikov, ki so zaključili svoje sodelovanje v podaljšanem obdobju opazovanja, ker so potrebovali ponovno zdravljenje (po presoji zdravnika), večji v skupini bolnikov, ki so prejemali risedronat, (48 bolnikov oziroma 41,7 %) kot v skupini bolnikov, ki so prejemali zoledronsko kislino (11 bolnikov oziroma 7,2 %).
Based on laboratory assessment, transient asymptomatic calcium levels below the normal reference range (less than 2.10 mmol/l) occurred in 2.3% of zoledronic acid-treated patients in a large clinical trial compared to 21% of zoledronic acid-treated patients in the Paget's disease trials.
Na podlagi laboratorijskih preiskav so ugotovili, da je do prehodnega asimptomatskega znižanja koncentracij kalcija pod okvir normalnih referenčnih vrednosti (pod 2,10 mmol/l) prišlo pri 2,3 % bolnikov, ki so prejemali zoledronsko kislino v obsežnem kliničnem preskušanju, v primerjavi z 21 %
For atrial fibrillation serious adverse events the pooled incidences were 1.3% for zoledronic acid and 0.8% for placebo.
Združeni incidenci atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, sta bili 1,3 % pri zoledronski kislini in 0,8 % pri placebu.
What Zoledronic acid Teva Generics looks like and contents of the pack Zoledronic acid Teva Generics is a clear and colourless solution for infusion.
Izgled zdravila Zoledronska kislina Teva Generics in vsebina pakiranja Zdravilo Zoledronska kislina Teva Generics je bistra brezbarvna raztopina za infundiranje.
Zoledronic acid is contraindicated during pregnancy (see section 4.3).
Uporaba zoledronske kisline v nosečnosti je kontraindicirana (glejte poglavje 4.3).
Zoledronic acid Teva Generics with food and drink Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with Zoledronic acid Teva Generics, as directed by your doctor.
Zdravilo Zoledronska kislina Teva Generics skupaj s hrano in pijačo Poskrbite, da boste pred zdravljenjem z zdravilom Zoledronska kislina Teva Generics in po njem pili dovolj tekočine (vsaj en do dva kozarca), kot vam bo naročil zdravnik.
Zoledronic acid significantly increased BMD at the lumbar spine, hip, and distal radius relative to treatment with placebo at all timepoints (6, 12, 24 and 36 months).
Učinek na mineralno gostoto kosti (bone mineral density - BMD) Zoledronska kislina je statistično značilno povečala mineralno gostoto kosti ledvene hrbtenice, kolka in distalnega dela koželjnice v primerjavi s placebom po vseh obdobjih opazovanja (po 6, 12, 24 in 36 mesecih).
Before stopping Zoledronic acid Teva Generics therapy If you are considering stopping Zoledronic acid Teva Generics treatment, please go to your next appointment and discuss this with your doctor.
Če nameravate prenehati z zdravljenjem z zdravilom Zoledronska kislina Teva Generics, se pri naslednjem pregledu o tem pogovorite z zdravnikom.
Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.
30-odstotno znižanje koncentracije zoledronske kisline ob koncu infundiranja, ni pa vplivalo na površino pod krivuljo plazemske koncentracije v odvisnosti od časa.
In the intravenous bolus studies, the doses that were well-tolerated decreased with increasing study duration: 0.2 and 0.02 mg/kg daily was well tolerated for 4 weeks in rats and dogs, respectively but only 0.01 mg/kg and 0.005 mg/kg in rats and dogs, respectively, when given for 52 weeks.
V študijah z intravenskimi bolusi so se odmerki, ki so jih živali dobro prenašale, zmanjševali s podaljševanjem študije: odmerek 0,2 oziroma 0,02 mg/kg na dan so podgane in psi dobro prenašali 4 tedne, medtem ko so tako podgane kot psi 52 tednov dolgo dajanje zdravila dobro prenašali le v odmerku 0,01 mg/kg oziroma 0,005 mg/kg.
The hip fracture event rate was 1.44% for zoledronic acid-treated patients compared to 2.49% for placebo-treated patients.
Delež zlomov kolka je bil 1,44 % v skupini z zoledronsko kislino v primerjavi z 2,49 % v skupini s placebom.
Headache, dizziness, sickness, vomiting, diarrhoea, pain in the muscles, pain in the bones and/or joints, pain in the back, arms or legs, flu-like symptoms (e.g. tiredness, chills, joint and muscle pain), chills, feeling of tiredness and lack of interest, weakness, pain, feeling unwell.
Glavobol, omotičnost, slabost, bruhanje, driska, bolečine v mišicah, bolečine v kosteh in/ali sklepih, bolečine v hrbtu, rokah ali nogah, gripi podobni simptomi (na primer utrujenost, mrazenje, bolečine v sklepih in mišicah), mrazenje, občutek utrujenosti in pomanjkanje zanimanja, šibkost, bolečine, slabo počutje.
The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse.
Običajni odmerek je 5 mg, in sicer vam ga da vaš zdravnik ali medicinska sestra enkrat na leto v obliki enkratne infuzije v veno.
In patients with a recent low-trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first zoledronic acid infusion.
Pri bolnikih z nedavnim zlomom kolka po lažji poškodbi je pred prvo infuzijo zoledronske kisline priporočen večji začetni odmerek vitamina D 50.000 do 125.000 i.e. peroralno ali intramuskularno.
In the HORIZON-RFT study zoledronic acid treatment significantly increased BMD at the total hip and femoral neck relative to treatment with placebo at all timepoints.
V študiji HORIZON-RFT je zdravljenje z zoledronsko kislino ob vseh časih opazovanja pomembno povečalo mineralno gostoto kosti celotnega kolka in vratu stegnenice v primerjavi s placebom.
Cyclic Olefin Polymer (COP) plastic bottle, fitted with a chlorobutyl/butyl rubber stopper and aluminium cap fitted with violet plastic flip off disc.
Plastenka iz cikloolefinskega polimera z zamaškom iz klorobutila/butila in pečatom iz aluminija z vijolično plastično dvižno zaporko.
LIST OF EXCIPIENTS Excipients: Mannitol, sodium citrate and water for injections.
Pomožne snovi: manitol, natrijev citrat in voda za injekcije.
If refrigerated, allow the refrigerated solution to reach room temperature before administration.
Če je raztopina zdravila ohlajena, pustite, da se pred uporabo segreje na sobno temperaturo.
Zoledronic acid Teva Generics must not be allowed to come into contact with any calcium-containing solutions.
Ne smete dovoliti, da bi zdravilo Zoledronska kislina Teva Generics prišla v stik z raztopino, ki vsebuje kalcij.
Zoledronic acid significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one year timepoint (see Table 2).
Učinek na morfometrično opredeljene zlome vretenc Zoledronska kislina je statistično značilno znižalo incidenco enega ali več novih zlomov vretenc tako v obdobju treh let kot tudi že po enem letu opazovanja (glejte preglednico 2).
Efficacy was demonstrated if non-inferiority to risedronate was shown sequentially with respect to the percentage change in lumbar spine BMD at 12 months relative to baseline in the treatment and prevention subpopulations, respectively.
Učinkovitost je bila dokazana, če se je pokazalo, da zoledronska kislina ni bila slabše od risedronata glede odstotne spremembe mineralne gostote kosti ledvene hrbtenice po 12 mesecih v primerjavi z izhodiščno vrednostjo, in sicer posebej v podskupini za zdravljenje in posebej v podskupini za preprečevanje osteoporoze.
Women of childbearing potential Zoledronic acid is not recommended in women of childbearing potential.
Ženske v rodni dobi Uporaba zoledronske kisline ni priporočena pri ženskah v rodni dobi.
It is supplied in multipacks containing 5 or 10 bags.
Na voljo je v skupnem pakiranju po 5 ali 10 vreč.
For osteoporosis, Zoledronic acid Teva Generics works for one year.
Za zdravljenje osteoporoze deluje zdravilo Zoledronska kislina Teva Generics eno leto.
Uncommon Influenza, nasopharyngitis
Preglednica 1 Infekcijske in parazitske bolezni občasni gripa, nazofagitis
Tetracycline label was detectable in all but one of 82 biopsies obtained from patients on zoledronic acid.
Označevanje s tetraciklini je bilo mogoče odkriti v vseh 82 biopsijskih vzorcih bolnic, ki so bile zdravljene z zoledronsko kislino z izjemo enega vzorca.
Concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates.
Sočasno zdravljenje osteoporoze je vključevalo: kalcitonin, raloksifen, tamoksifen,
Renal impairment has been observed following the administration of zoledronic acid (see section 4.8), especially in patients with pre-existing renal dysfunction or other risks including advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy (see section 4.5), or dehydration occurring after zoledronic acid administration.
Po odmerjanju zoledronske kisline so opažali okvare ledvic (glejte poglavje 4.8), zlasti pri bolnikih s predhodno ledvično disfunkcijo ali z drugimi dejavniki tveganja, kar vključuje višjo starost bolnika, sočasno uporabo nefrotoksičnih zdravil, diuretičnega zdravljenja (glejte poglavje 4.5) ali dehidracijo po odmerjanju zoledronske kisline.
Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy The efficacy and safety of zoledronic acid in the treatment and prevention of osteoporosis associated with long-term systemic glucocorticoid therapy were assessed in a randomised, multicentre, double-blind, stratified, active-controlled study of 833 men and women aged 18-85 years (mean age for men 56.4 years; for women 53.5 years) treated with > 7.5 mg/day oral prednisone (or equivalent).
Klinična učinkovitost pri osteoporozi zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi Učinkovitost in varnost zdravila pri zdravljenju in preprečevanju osteoporoze, do katere pride zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi, so ocenjevali v randomizirani, multicentrični, dvojno slepi, stratificirani, aktivno kontrolirani študiji z 833 moškimi in ženskami, starimi od 18 do 85
- if you have had sections of your intestine removed.
- če so vam odstranili dele črevesa.
Special populations (see section 4.2)
Posebne skupine bolnikov (glejte poglavje 4.2) Okvara ledvic
85% of patients were bisphosphonate-naïve.
85 % bolnic prej še ni prejemalo difosfonatov.
There was no progressive reduction of bone turnover markers with repeated annual dosing.
Pri ponovljenem odmerjanju enkrat letno ni prišlo do progresivnega zniževanja vrednosti označevalcev pregradnje kosti.
Treatment with zoledronic acid resulted in a 6.7% increase in BMD at the lumbar spine, 6.0% at the total hip, 5.1% at the femoral neck, and 3.2% at the distal radius over 3 years as compared to placebo.
Zdravljenje z zoledronsko kislino je v obdobju 3 let zvečalo mineralno gostoto kosti ledvene hrbtenice za 6,7 %, celotnega kolka za 6,0 %, vratu stegnenice za 5,1 % in distalnega dela koželjnice za 3,2 % v primerjavi s placebom.
Tel/Tél: +32 3 820 73 73
/S.A./AG Tel/Tél: +32 3 820 73 73
Clinical efficacy in the treatment of Paget's disease of the bone Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Klinična učinkovitost pri zdravljenju Pagetove bolezni kosti Zoledronsko kislino so proučevali pri bolnicah in bolnikih, starejših od 30 let, z rentgenološko potrjeno primarno blago do zmerno Pagetovo boleznijo kosti (mediana aktivnost alkalne fosfataze v serumu je bila 2,6 do 3-krat večja od zgornje meje starostno specifičnega normalnega referenčnega območja v času vstopa v študijo).
Renal failure requiring dialysis or with a fatal outcome has rarely occurred in patients with underlying renal impairment or with any of the risk factors described above.
Pri bolnikih s predhodno okvaro ledvic ali s katerim od zgoraj navedenih dejavnikov tveganja je redko prišlo do ledvične odpovedi, zaradi katere bi bila potrebna dializa ali bi se končala s smrtjo.
Zoledronic acid Teva Generics has no or negligible influence on the ability to drive and use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Zoledronska kislina Teva Generics nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Any unused solution should be discarded.
Morebitno neuporabljeno raztopino zavrzite.
No dose adjustment is necessary in patients with creatinine clearance ≥ 35 ml/min.
Za bolnike z očistkom kreatinina ≥ 35 ml/min ni potrebno prilagajanje odmerjanja.
In the HORIZON - Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
V študiji HORIZON - študiji pomembnih zlomov (Pivotal Fracture Trial [PFT], glejte poglavje 5.1) je bila skupna incidenca atrijske fibrilacije pri bolnikih, ki so prejemali zoledronsko kislino, 2,5 % (pri 96 od 3.862 bolnikov), pri bolnikih, ki so prejemali placebo, pa 1,9 % (pri 75 od 3.852 bolnikov).
The inter- and intra-subject variation for plasma clearance of zoledronic acid was shown to be 36% and 34%, respectively.
Pokazali so, da je variabilnost plazemskega očistka zoledronske kisline med preiskovanci 36 %, pri posameznem preiskovancu pa 34 %.
Osteonecrosis of the jaw has been reported in patients treated with zoledronic acid.
O osteonekrozi čeljusti so poročali pri bolnikih, ki so prejemali zolendronsko kislino.
There was no accumulation of the active substance in plasma after multiple doses given every 28 days.
Po večkratnih odmerkih zdravila, danih vsakih 28 dni, se zdravilna učinkovina ni kopičila v plazmi.
6.6 Special precautions for disposal and other handling
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Samo za enkratno uporabo.
Paget's disease of the bone
Pagetova bolezen kosti
België/Belgique/Belgien Teva Pharma Belgium N.V. Tel/Tél: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Tel/Tél: +32 3 820 73 73
• Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each zoledronic acid dose.
• Pred vsakim odmerjanjem zoledronske kisline je treba izračunati očistek kreatinina glede na dejansko telesno maso po Cockcroft-Gaultovi formuli.
Rare (may affect up to 1 in 1,000 people)
Redki (pojavijo se lahko pri največ 1 od 1. 000 bolnikov):
The majority of patients continued to receive glucocorticoids for the one year duration of the trial.
Bolniki so v letu, ko je potekala študija, večinoma nadaljevali zdravljenje z glukokortikoidi.
The use of zoledronic acid in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zoledronske kisline pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved pri tej populaciji.
Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Zoledronic acid Teva Generics.
Mogoče vam bo zdravnik svetoval, da vsaj prvih deset dni po prejemu zdravila Zoledronska kislina Teva Generics jemljete dodatke kalcija in vitamina D (na primer v obliki tablet).
MARKETING AUTHORISATION NUMBER(S) EU/1/14/912/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/14/912/001
It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving Zoledronic acid Teva Generics, as directed by your healthcare provider.
Pomembno je, da v nekaj urah pred prejemom zdravila Zoledronska kislina Teva Generics popijete vsaj en ali dva kozarca tekočine (na primer vode), kakor vam naroči zdravstveni delavec, s katerim sodelujete.
Zoledronic acid Teva Generics is not recommended for anyone under 18 years of age.
Otroci in mladostniki Uporaba zdravila Zoledronska kislina Teva Generics ni priporočljiva pri starosti pod 18 let.
Follow carefully all instructions given to you by your doctor or nurse.
Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika ali medicinske sestre.
The use of Zoledronic acid Teva Generics in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Uporaba zdravila Zoledronska kislina Teva Generics je pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
B-CTx was significantly reduced by 61% below baseline levels at 12 months and was sustained at 55% below baseline levels at 36 months.
Vrednosti beta C-telopeptida so se po 12 mesecih statistično značilno znižale za 61 % od izhodiščnih vrednosti, znižanje se je po 36 mesecih ohranilo na vrednosti 55 % pod izhodiščnimi vrednostmi.
Not known (frequency cannot be estimated from the available data) Severe allergic reactions including dizziness and difficulty breathing, swelling mainly of the face and throat, decreased blood pressure, dehydration secondary to post-dose symptoms such as fever, vomiting and diarrhoea.
Hude alergijske reakcije, vključno z omotičnostjo in oteženim dihanjem, otekanje predvsem v obraz in grlo oziroma žrelo, znižan krvni tlak, dehidracija zaradi simptomov po odmerjanju, kot so zvišana telesna temperatura, bruhanje in diareja.
Bone biopsies were obtained from the iliac crest 1 year after the third annual dose in 152 post-menopausal patients with osteoporosis treated with zoledronic acid (N=82) or placebo (N=70).
Eno leto po tretjem letnem odmerku so 152 postmenopavzalnim bolnicam z osteoporozo, ki so se zdravile z zoledronsko kislino (N=82) oziroma s placebom (N=70), opravili biopsijo kosti iz grebena črevnice (crista iliaca).
• Reminder card with the following key messages: o Need to calculate creatinine clearance based on actual body weight using the CockcroftGault formula before each treatment with Zoledronic acid Teva Generics o Contraindication in patients with creatinine clearance < 35 ml/min o Contraindication in pregnancy and in breast-feeding women due to potential teratogenicity o Need to ensure appropriate hydration of the patient especially those at an advanced age and those receiving diuretic therapy o Need to infuse Zoledronic acid Teva Generics slowly over a period of no less than 15 minutes o Once-yearly dosing regime o Adequate calcium and vitamin D intake are recommended in association with zoledronic acid administration o Need for appropriate physical activity, non-smoking and healthy diet
• Opomnik z naslednjimi ključnimi sporočili: Potreba izračuna očistka kreatinina glede na dejansko telesno maso po Cockcroft-Gaultovi formuli pred vsakim zdravljenjem z zdravilom Zoledronska kislina Teva Generics o kontraindikacija pri bolnikih z očistkom kreatinina < 35 ml/min, o kontraindikacije med nosečnostjo in dojenjem zaradi možne teratogenosti,
Bone specific alkaline phosphatase (BSAP), serum N-terminal propeptide of type I collagen (P1NP) and serum beta-C-telopeptides (b-CTx) were evaluated in subsets ranging from 517 to 1,246 patients at periodic intervals throughout the study.
V celotnem poteku študije so podskupinam, ki so zajemale od 517 do 1.246 bolnic, v rednih intervalih pregledovali kostno specifično alkalno fosfatazo (bone specific alkaline phosphatase - BSAP), Nkončni propeptid kolagena tipa I (N-terminal propeptide of type I collagen - P1NP) v serumu in beta C-telopeptide (b-CTx).
Pharmacodynamic effects The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone.
Difosfonati delujejo selektivno na kosti zaradi svoje velike afinitete do mineralizirane kosti.
All women received 1,000 to 1,500 mg elemental calcium and 400 to 1,200 IU of vitamin D supplements daily.
Vse ženske so prejemale dodatke 1.000 do 1.500 mg elementarnega kalcija in vitamina D v odmerkih 400 do 1.200 i.e. dnevno.
Tell your dentist immediately if you experience such symptoms.
Če pride do navedenih simptomov, takoj obvestite svojega zobozdravnika.
Talk to your doctor before you are given Zoledronic acid Teva Generics: - if you are being treated with any other bisphosphonate medicine, since the combined effects of these medicines taken together with Zoledronic acid Teva Generics are unknown.
- če se zdravite z zdravilom, ki vsebuje kateri koli drug difosfonat, saj skupni učinki jemanja teh zdravil skupaj z zdravilom Zoledronska kislina Teva Generics niso znani.
Not known** Osteonecrosis of the jaw (see sections 4.4 and 4.8 Class effects)
neznana** osteonekroza čeljusti (glejte poglavji 4.4